{"id":"NCT01109173","sponsor":"Alcon Research","briefTitle":"Confirmatory Study Nepafenac 0.3%","officialTitle":"Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-05","completion":null,"firstPosted":"2010-04-23","resultsPosted":"2012-11-30","lastUpdate":"2012-11-30"},"enrollment":2120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cataract"],"interventions":[{"type":"DRUG","name":"Nepafenac Ophthalmic Suspension, 0.3%","otherNames":[]},{"type":"DRUG","name":"Nepafenac Ophthalmic Suspension, 0.1%","otherNames":["NEVANACÂ®"]},{"type":"OTHER","name":"Nepafenac Ophthalmic Suspension 0.3% Vehicle","otherNames":[]},{"type":"OTHER","name":"NEVANAC Vehicle","otherNames":[]}],"arms":[{"label":"Nepafenac 0.3%","type":"EXPERIMENTAL"},{"label":"NEVANAC","type":"ACTIVE_COMPARATOR"},{"label":"Nepafenac Vehicle 0.3%","type":"PLACEBO_COMPARATOR"},{"label":"NEVANAC Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.","primaryOutcome":{"measure":"Percentage of Patients Cured at Day 14","timeFrame":"Day 14","effectByArm":[{"arm":"Nepafenac 0.3%","deltaMin":68.4,"sd":null},{"arm":"NEVANAC","deltaMin":70,"sd":null},{"arm":"Nepafenac Vehicle 0.3%","deltaMin":34,"sd":null},{"arm":"NEVANAC Vehicle","deltaMin":35.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":817},"commonTop":[]}}